Biofarmaceutica clinical-stage che sviluppa Deraphan contro l'agitazione associata all'Alzheimer.
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Series B Germany's Exciva closed a 51 million euro Series B co-led by EQT Life Sciences (LSP Dementia Fund) and Gimv to take its therapy for Alzheimer's-related agitation into Phase 2. | $59.2M |
| Oct 2021 | Series A German biotech Exciva raised a EUR 9M Series A led by Andera Partners to treat agitation in Alzheimer's disease. | $10.6M |